Ubiquitination and downregulation of ErbB2 and estrogen receptor‐alpha by kinase inhibitor MP‐412 in human breast cancer cells
- 18 April 2011
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (9) , 2279-2286
Abstract
ErbB2 has been proven to be an important target for breast cancer therapy. MP‐412 is a dual ErbB2 and epidermal growth factor receptor tyrosine kinase inhibitor belonging to an irreversible‐type anilinoquinazoline derivative. We demonstrate herein that along with the kinase inhibition, MP‐412 has the ability to induce ubiquitination, internalization, and degradation of ErbB2 in several human breast cancer cell lines at concentrations relatively higher than those required for kinase inhibition. Another irreversible inhibitor, CI‐1033, showed similar activity, while the reversible compounds were ineffective, suggesting a crucial role of covalent bonding functionality in these effects. In MCF7 cells, MP‐412 depleted not only ErbB2 but also estrogen receptor (ER)‐α, and to some extent, affected Raf‐1, while MP‐412 activated Hsp70 expression. Moreover, we observed that MP‐412 increased immunocomplexing of Hsp70 with ErbB2 and ER‐α, with simultaneous induction of ubiquitination of these client proteins. Furthermore, in combination with proteasome inhibitor, MP‐412 resulted in the noticeable accumulation of ErbB2 and ER‐α in the detergent insoluble fraction of cell lysates. These results suggest that MP‐412 acts as an inhibitor of Hsp90 function, whereas MP‐412 did not bind directly to ATP‐binding site of Hsp90, unlike geldanamycin. We also found that new protein synthesis was involved in the activity of MP‐412 on Hsp90 modulation. Since downregulation of ErbB2 and ER‐α by accelerating the ubiquitin‐proteolysis system will become an attractive approach for breast cancer therapy, we expect MP‐412 to be a lead compound for the drug design and the development of such agents. J. Cell. Biochem. 112: 2279–2286, 2011.Keywords
This publication has 28 references indexed in Scilit:
- Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligaseProceedings of the National Academy of Sciences, 2009
- Molecular Mechanism of Inhibition of the Human Protein Complex Hsp90–Cdc37, a Kinome Chaperone–Cochaperone, by Triterpene CelastrolAngewandte Chemie International Edition, 2009
- Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stabilityMolecular Cancer, 2008
- The UPS: a promising target for breast cancer treatmentBMC Biochemistry, 2008
- Quercetin‐induced ubiquitination and down‐regulation of Her‐2/neuJournal of Cellular Biochemistry, 2008
- A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cellsMolecular Cancer Therapeutics, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapyThe EMBO Journal, 2002
- Polyubiquitination and Proteasomal Degradation of the p185c-B-2 Receptor Protein-tyrosine Kinase Induced by GeldanamycinJournal of Biological Chemistry, 1996
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987